Inter-ethnic differences-how important is it in cancer treatment?

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 8, 2011, Pages 356-361

  Ling, Winnie Hy ^a   Lee, Soo Chin ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Drug response; Inter ethnic; Pharmacogenetics

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; OXALIPLATIN; TAMOXIFEN; WARFARIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASIAN; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CANCER THERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEBRILE NEUTROPENIA; HAPLOTYPE; HEAD AND NECK CANCER; HUMAN; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHYSICIAN; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; THROMBOEMBOLISM;

EID: 80052827117     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-423.
2. U.S Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Collection of race and ethnicity data in clinical trials. Clinical Medical 2005.
3. Taylor A, Ziesche S, Yancy C, Carson P, D'Agostino, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. N Engl J Med 2004;351:2049-2057.
4. Schwartz RS. Racial profi ling in medical research. N Engl J Med 2001;344:1392-1393.
5. Schmitt E. For 7 million people in census, one race category isn't enough. New York Times; 13 March, 2001.
6. Blann A, Herwitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999;107:207-209.
7. Dang MT, Hambleton J, Kayser SR. The infl uence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39:1008-1012.
8. Yu HC, Chan T Y, Critchley JA, Woo KS. Factors determining the maintenance warfarin dose in Chinese patients. QJM 1996;89:127-135.
9. Zhao F, Loke C, Rankin S, Guo JY, Lee HS, Wu TS, et al. Novel CYP269 genetic variants in Asian subjects and their infl uence on maintenance warfarin dose. Clin Pharmacol Ther 2004;76:210-219.
10. Lee SC, Ng SS, Chong P Y, Rost S, Guo JY, Yap HL, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006;79:197-205.
11. Rieder M, Reiner A, Gage B, Nickerson D, Eby C, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-2293.
12. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62:185-189.
13. Beith JM, Goh BC, Yeo W, Sullivan A, Lim S, Zhong S, et al: Inter-ethnic differences in the myelotoxicity of adriamycin/ cyclophosphamide (AC) or adjuvant breast cancer. Proc American Society of Clinical Oncology 2002;21:abstract 252.
14. Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008;8:139-146.
15. Tham LS, Holford N, Hor SY, Tan T, Wang LZ, Lim RC, et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha and constituitive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 2007;13:7126-7132.
16. Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008;18:623-631.
17. Millward MJ, Boyer MJ, Lehnert M, Clarke S, Rischin D, Goh BC, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449-454.
18. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671.
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
20. Perng RP, Shih JF, Chen YM, Chou KC, Lee YC, Tsai CM. A phase II study of single agent docetaxel chemotherapy for non-small cell lung cancer. Jpn J Clin Oncol 2000;30:429-434.
21. Muruyama R, Nishiwaki Y, Tamura T, Yamanoto N, Tsuboi M, Nakagawa K, et al. Phase III study V-15-13 of gefi tinib vs docetaxel in previously treated patients with non small cell lung cancer. J Clin Oncol 2008;26:4244-4258.
22. Bruno R, Hille D, Riva A, Huinnink W, Van Oosterom A, Kaye S, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196.
23. Goh BC, Lee SC, Wang LZ, F Lu, Guo JY, Lamba J, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002;20:3683-3690.
24. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian cancer. J Clin Oncol 2007;25:4528-4535.
25. Haller D, Cassidy J, Clarke S, Cunningham D, Van Cutsem E, Hoff P, et al. Potential regional differences for the tolerability profi les of Fluropyrimidines. J Clin Oncol 2008;26:2118-2123.
26. Marsh S, Collie-Duguid ES, Li T, Liu X, Mcleod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian population. Genomics 1999;58:310-312.
27. Jiang H. Overview of gefi tinib in non-small cell lung cancer: an Asian perspective. Japanese J Clin Oncol 2009;39:137-150.
28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005;97:339-346.
29. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefi tinib. Lancet 2003;361:137-139.
30. Calvo E, Baselga J. Ethnics differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24:2158-2163.
31. Tan SH, Lee SC, Goh BC. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008;14:8027-8041.
32. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-243.
33. Goetz M, Rae J, Suman V, Safgren S, Ames M, Visscher D, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of effi cacy and hot fl ushes. J Clin Oncol 2005;23:9312-9318.
34. Lim HS, Lee HJ, Lee KS, Lee ES, Jang IJ, Ro JS, et al. Clinical implications of CYP2D6 genotypes predictrive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-3845.